SouthViews No. 180, 20 May 2019
Colombia’s Biogenerics Regulation A Preliminary Court Decision in favour of Public Health
By Carolina Gómez
The Council of State of Colombia’s recent ruling on the abbreviated pathway for marketing authorization of biogenerics is a valuable step towards acceptance and uptake of biogenerics, favoring public health, access and market competition.
In 2014, after several years of discussion and heated debate, Colombia issued a regulation for sanitary registration of biotechnological medicines, including biogenerics. The regulation explicitly included an abbreviated pathway for the registration of biogenerics, which allows for reduction or, in some cases, even waivers of comparative efficacy clinical trials. PK/PD and inumunogenicity studies are required.Download the SouthViews:
Colombia’s Biogenerics Regulation A Preliminary Court Decision in favour of Public Health
This article was tagged: Access to Health, Access to Medicines, Biogenerics, Biogenerics Regulation, Biotechnology, Colombia, Inumunogenicity Studies, Public Health
